Sam, Am I selling my shares now?
At the low of the
Sam, Am I selling my shares now?
At the low of the year? Of course not!
I did receive an email response from Todd today, as well, and still sounded sort of upbeat and optimistic (of course, it is his job to be optimistic) and I will surely wait and see what the remainder of the months of August will bring for us, and whether there will really be positive things happening prior to those CCs.
I also still see a chance that positive results of the lab tests and the approval from the FDA of the pre-IND application might finally trigger BARDA to grant some funding.
In addition, I stated several times before that - in my view - all that is really missing for gnbt is funding to get a first ball rolling, BARDA and a CV vaccine would still be the best option, and this toxic financing be the worst, but then GNBT can tap into a lot of potential and make a lot of good things happen.
So let's see if Joe and his team are at leat able to make best use of the $2m of capital nor available to them and at least get some bells rolling.
I do agree with previous posters though, that I would also rather like to see some of the existing subs to be jump started and help make significant revenues than seeing additional acquisitions being made (other than AltuCell, which has been discussed for such a long time that I would not consider it a "new" acquisition anymore) or new lines of business to be opened
I will give Joe at least till the end of August to create some positive news, and then I will decide what to do with my shares.
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....
Continue Reading
Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...
Continue Reading
AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...
Continue Reading
A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...
Continue Reading
History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...
Continue Reading
You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...
Continue Reading
Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...
Continue Reading
Top 5 Most Recently Viewed Articles
Magna5 Achieves Recognition in Inc. Rankings In a proud moment for the team, Magna5 has ranked No. 39 on the coveted Inc. Regionals: Northeast list. This annual evaluation highlights the fastest-growing private companies within this region, emphasizing the remarkable impact of independent small businesses in various sectors. The company’s recognition showcases its...
Continue Reading
Appian Recognized as a Leader in Process Orchestration Appian has made headlines recently by being named a leader in a prominent assessment of process orchestration products. This recognition by Everest Group positions Appian at the forefront of innovations that empower businesses to enhance their operational workflows and increase efficiency. What Is Process...
Continue Reading
Analysis of Financial Institutions’ Recent Performance Recently, Financial Institutions (NASDAQ:FISI) received an Equal Weight rating from Stephens, reaffirming a price target of $28.50. The company delivered impressive financial results, with earnings per share (EPS) reported at $0.84 for GAAP and $0.82 for operating earnings. These figures exceeded both the company's...
Continue Reading
United Airlines Earnings Report Overview United Airlines Holdings, Inc. (NASDAQ: UAL) is on the brink of announcing its third-quarter earnings results. Investors and analysts alike are eagerly anticipating these numbers, especially as the company is projected to report a decrease in earnings per share compared to the previous year. Expected Earnings Decline Analysts...
Continue Reading
Ontex's Strategic Share Buyback Program Ontex is making headlines with its ongoing program to acquire treasury shares, which marks a significant move for the company. The decision to initiate this buyback was formally disclosed in accordance with the regulations established by the Belgian government. This proactive strategy is designed to enhance shareholder value and...
Continue Reading
